Calculating And Understanding Particulate Contamination Risk - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Calculating And Understanding Particulate Contamination Risk
The author presents a method to calculate the relationship between supply air volume flow and airborne particle concentrations. These methods and approaches facilitate the overall understanding of airborne contaminants and provide valuable information when designing facilities and processes for sterile manufacturing.


Pharmaceutical Technology Europe
Volume 23, Issue 3

Molecular diffusion


Figure 2: Diffusion of particles.
Gas molecules colliding with airborne particles give rise to diffusive spreading (Figure 2). The effect of molecular diffusion may be considered when airborne particles are small (microscopic), which may occur in cleanrooms and clean areas.

Contamination risk — a model




Acknowledging the fact that cleanroom operators are often the main source of microorganisms, it can be useful to study the probability that microorganisms will contaminate certain areas associated with operators. To calculate the gravitation deposition of a concentration of airborne viable particles, Whyte describes an equation (Equation 1).5




The size of viable airborne particles from humans in a cleanroom environment is in the range of 5–20 m. An assumption can be made that the average viable particle size is 12 m. Using Stokes Law, Whyte shows that the settling velocity for a 12 m particle in air is 0.462 cm/s (Equation 2).

The knowledge of settling velocity is useful in volumes where the particles are only affected by gravity and not from major airflow routes such as in cleanrooms. In a pharmaceutical environment, however, air is used to create barriers with air velocities much higher than 0.462 cm/s. In critical areas using UDF units, common air velocities range between 0.3–0.5 m/s or 30–50 cm/s. Compared with the settling time of a 12 m particle (0.462 cm/s) affected only by gravity, the convective effect on the particle in a critical area will be dominating and the effect of gravity can often be neglected.3


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here